FIELD: chemistry.
SUBSTANCE: invention relates to a crystalline form of 4-[2-(2,4,6-trifluorophenoxymethyl)phenyl]piperidine hydrochloride which is characterised by an X-ray powder diffraction profile having diffraction peaks at the following values of 2Θ: 4.44±0.20, 10.22±0.20, 17.16±0.20 and 21.78±0.20. The present invention also relates to a pharmaceutical composition containing a crystalline form of 4-[2-(2,4,6-trifluorophenoxymethyl)phenyl]piperidine hydrochloride and having norepinephrine and serotonin reuptake inhibitor action, methods of producing said crystalline salt and use of the crystalline salt to treat diseases, e.g., pain syndrome etc.
EFFECT: novel crystalline form of a compound which can be used in treating a range of diseases is obtained and described.
11 cl, 8 ex, 5 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| 4-[2-(2-FLUOROPHENOXYMETHYL)PHENYL]PIPERIDINE COMPOUNDS | 2009 |
|
RU2515612C2 |
| COMPOUND FOR USE IN TREATING NEUROGENIC ORTHOSTATIC HYPOTENSION | 2017 |
|
RU2723095C1 |
| 3-PHENOXYMETHYL-PYRROLIDINE COMPOUNDS | 2010 |
|
RU2535669C2 |
| METHODS OF TREATMENT OF BIPOLAR DISORDER | 2011 |
|
RU2653408C2 |
| 4-[(3-FLUOROPHENOXY)PHENYLMETHYL]PIPERIDINE METHANESULPHONATE: USE, SYNTHESIS METHOD AND PHARMACEUTICAL COMPOSITIONS | 2007 |
|
RU2412169C2 |
| NOVEL CHROMAN-2-ONE DERIVATIVES AND USE THEREOF AS MONOAMINE NEUROMEDIATOR REUPTAKE INHIBITORS | 2005 |
|
RU2382040C2 |
| METHOD OF TREATING ATTENTION DEFICIT/HYPERACTIVITY SYNDROME | 2010 |
|
RU2556585C2 |
| SOLID FORMS OF 3-(5-AMINO-2-METHYL-4-OXO-4H-QUINAZOLIN-3-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND THEIR PHARMACEUTICAL COMPOSITIONS AND USE | 2012 |
|
RU2611007C2 |
| AZOLE COMPOUNDS | 2009 |
|
RU2493154C2 |
| 2-PHENYLETHYLAMINO DERIVATIVES AS CALCIUM AND/OR SODIUM CHANNEL MODULATORS | 2006 |
|
RU2397160C9 |
